ArticleFrontiers in aging neuroscience2024
Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021.
Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Case Definitions and Data Sources for NNCSS Parkinson Disease Surveillance: A Systematic Review.JAMA network open · 2026Pooled it
- Efficacy and safety of MRI-guided focused ultrasound lesioning for tremor-dominant Parkinson Disease: A systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.Acta neuropsychiatrica · 2026Pooled it
- Glymphatic Dysfunction in Parkinson's Disease: A Systematic Review and Meta-Analysis of Neuroimaging Studies.Movement disorders clinical practice · 2026Pooled it
- Pharmacological effects and mechanisms of curcumin in animal models of Parkinson's disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Comparative efficacy of traditional Chinese medicine qigong exercise on motor and non-motor outcomes in Parkinson's disease: a network meta-analysis.Frontiers in neurologyPooled it
- Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial.Movement disorders : official journal of the Movement Disorder Society · 2026Trial
- A randomized safety and feasibility crossover trial of two Mediterranean-ketogenic interventions in individuals with Parkinson's disease.Journal of Parkinson's disease · 2026Trial
- Association between C9orf72 G4C2 repeat length and idiopathic Parkinson's disease in a Turkish cohort.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Progressive Cognitive Decline and Pyramidal Signs in a Patient With a Novel Homozygous c.395A>T; p.Lys132Met Mutation in CHCHD2.Clinical case reports · 2026Article
- Neuroinflammation and noradrenergic modulation with β2-adrenoceptors: Emerging therapeutic targets for Parkinson's diseases.Neural regeneration research · 2026Article
- Demographic Shortcuts Account for Most of the Apparent Accuracy of Four-Class Gait-Based Differential Diagnosis in Neurodegenerative Disease: An Interpretability-Driven Audit of Machine Learning on a Public Gait Benchmark.Bioengineering (Basel, Switzerland) · 2026Article
- Hinokitiol as a Potential GPX4 Allosteric Modulator to Prevent Ferroptosis-mediated Neurodegeneration in Parkinson's Disease.Neurochemical research · 2026Article
- Eye-Tracking Assessment of Visual, Oculomotor, and Pupillary Biomarkers During Reading in Parkinson's Disease.Life (Basel, Switzerland) · 2026Article
- Repurposing Anticancer Drugs in Parkinson's Treatment: Molecular Pathways Driving Neuroprotection and Therapeutic Advancement.Molecular neurobiology · 2026Review
- NabioRxiv : the preprint server for biology · 2026Article
- Fungal-Derived Decahydrofluorene Alkaloids Promote Mitochondrial Resilience and Neuroprotection in Cellular and Animal Models of Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2026Article
- Pallidal Volumetry and Neutrophil-to-Lymphocyte Ratio in Differentiating Progressive Supranuclear Palsy from Parkinson's Disease.Diseases (Basel, Switzerland) · 2026Article
- Toward Interpretable Voice-Based Parkinson's Disease Screening via Joint Transfer Function-Feature-Classifier-Ensemble Selection.Bioengineering (Basel, Switzerland) · 2026Article
- Parkinson's Disease and Respiratory Failure: Epidemiologic Insights of Two Decades From the CDC-WONDER Database.Brain and behavior · 2026Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: In light of the escalating global incidence of Parkinson's disease and the dearth of therapeutic interventions that can alter the disease's course, there exists an urgent necessity to comprehensively elucidate and quantify the disease's global burden. Methods: This study analyzed the incidence, prevalence, and disability-adjusted life years (DALYs) of Parkinson's disease at global, regional, and national levels based on the Global Burden of Disease Study 2021. Bayesian age-period cohort (BAPC) analysis was used to predict the burden in Parkinson's disease from 2022 to 2035. Results: In 2021, 11.77 million people worldwide had Parkinson's disease. Age-standardized rates of incidence, prevalence, and DALYs increased to 15.63/100,000, 138.63/100,000, and 89.59/100,000. The burden of Parkinson's disease were higher in males than in females, and showed an increase and then a slight decrease with age. The disease burden was highest in East Asia. BAPC projection showed an increase in all metrics by 2035 except for a slight decrease in the age-standardized DALYs rates. Conclusion: The global burden of Parkinson's disease has risen over the past 32 years, and there is a need to focus on key populations, as well as to improve health policies to prevent and treat Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.